arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Armata Pharmaceuticals, Inc.

ARMP
$4.66 ▼ -0.01 (-0.21%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
54 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Armata Pharmaceuticals, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $170.2M
Dividend Yield
Revenue Growth
Op. Margin
ROIC 2.2%
FCF / Share $-0.16
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

54-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-115.35M
↓ -1666.1%
FCF / Share Free cash flow per share
$-0.16
↑ +24.6%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
99
Cash Quality
28

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 54 quarters